Ost-müük Cymabay Therapeu - CBAY CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.07 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
| Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 2.7 |
| Avatud* | 2.63 |
| Aastane muutus* | -6.74% |
| Päeva ulatus* | 2.63 - 2.83 |
| 52 nädala ulatus | 1.67-8.74 |
| Keskmine maht (10 päeva) | 2.17M |
| Keskmine maht (3 kuud) | 21.16M |
| Turukapitalisatsioon | 722.33M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 84.68M |
| Tulu | N/A |
| EPS | -1.25 |
| Dividendid (% kasumist) | N/A |
| Beeta | 0.27 |
| Järgmine tuluaruande kuupäev | Mar 15, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 2.82 | 0.13 | 4.83% | 2.69 | 2.83 | 2.63 |
| Jun 28, 2022 | 2.70 | -0.13 | -4.59% | 2.83 | 2.83 | 2.65 |
| Jun 27, 2022 | 2.80 | 0.07 | 2.56% | 2.73 | 3.01 | 2.53 |
| Jun 24, 2022 | 2.74 | 0.15 | 5.79% | 2.59 | 2.76 | 2.31 |
| Jun 23, 2022 | 2.55 | 0.21 | 8.97% | 2.34 | 2.55 | 2.29 |
| Jun 22, 2022 | 2.37 | 0.36 | 17.91% | 2.01 | 2.42 | 1.97 |
| Jun 21, 2022 | 2.03 | 0.07 | 3.57% | 1.96 | 2.08 | 1.96 |
| Jun 17, 2022 | 1.94 | 0.06 | 3.19% | 1.88 | 2.01 | 1.84 |
| Jun 16, 2022 | 1.88 | 0.00 | 0.00% | 1.88 | 1.89 | 1.79 |
| Jun 15, 2022 | 1.91 | -0.07 | -3.54% | 1.98 | 1.99 | 1.83 |
| Jun 14, 2022 | 1.99 | -0.09 | -4.33% | 2.08 | 2.12 | 1.98 |
| Jun 13, 2022 | 2.09 | 0.00 | 0.00% | 2.09 | 2.13 | 2.01 |
| Jun 10, 2022 | 2.22 | -0.10 | -4.31% | 2.32 | 2.39 | 2.17 |
| Jun 9, 2022 | 2.37 | 0.07 | 3.04% | 2.30 | 2.44 | 2.30 |
| Jun 8, 2022 | 2.35 | 0.11 | 4.91% | 2.24 | 2.37 | 2.24 |
| Jun 7, 2022 | 2.29 | 0.20 | 9.57% | 2.09 | 2.33 | 2.09 |
| Jun 6, 2022 | 1.92 | -0.08 | -4.00% | 2.00 | 2.05 | 1.92 |
| Jun 3, 2022 | 2.02 | 0.04 | 2.02% | 1.98 | 2.07 | 1.98 |
| Jun 2, 2022 | 2.01 | 0.09 | 4.69% | 1.92 | 2.02 | 1.92 |
| Jun 1, 2022 | 1.97 | 0.04 | 2.07% | 1.93 | 1.98 | 1.90 |
Cymabay Therapeu Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kogutulu | 0 | 10 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 25.586 | 31.325 | 72.912 | 108.15 | 52.602 | 87.582 |
| Müük/Üldine/admin kulud, kokku | 9.645 | 12.387 | 14.381 | 19.238 | 17.425 | 23.04 |
| Uuringud ja arendus | 15.941 | 18.938 | 58.124 | 83.837 | 35.882 | 64.542 |
| Tulud majandustegevusest | -25.586 | -21.325 | -72.912 | -108.15 | -52.602 | -87.582 |
| Intressitulud (kulu), muud tulud, neto | -1.161 | -0.459 | 3.652 | 5.342 | 1.616 | -2.416 |
| Muud, neto | 0.076 | -5.773 | -3.288 | 0 | ||
| Netotulu enne makse | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Netotulu pärast makse | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Netotulu enne erikulusid | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Netotulu | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Arvestatav tulu, v a erikulud | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Arvestatav tulu, koos erikuludega | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Jaotamisele kuuluv netotulu | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Keskmine jaotamisele kuuluv aktsia kohta | 23.447 | 34.904 | 57.8083 | 67.0331 | 68.8931 | 71.0553 |
| Jaotatav EPS, v a erakorralised kulud | -1.1375 | -0.78951 | -1.25498 | -1.53369 | -0.74007 | -1.26659 |
| Jaotamisele kuuluv normaal-EPS | -1.1375 | -0.78951 | -1.24794 | -1.45798 | -0.75031 | -1.26659 |
| Tulu | 10 | 0 | ||||
| Erakorralised kulud kokku | 0 | |||||
| Ootamatud kulutused (tulu) | 0.407 | 5.075 | -0.705 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 17.618 | 23.266 | 22.189 | 24.509 | 24.502 |
| Müük/Üldine/admin kulud, kokku | 5.236 | 6.521 | 5.179 | 6.104 | 6.087 |
| Uuringud ja arendus | 12.382 | 16.745 | 17.01 | 18.405 | 18.415 |
| Tulud majandustegevusest | -17.618 | -23.266 | -22.189 | -24.509 | -24.502 |
| Intressitulud (kulu), muud tulud, neto | 0.067 | 0.044 | -0.493 | -2.034 | -3.267 |
| Netotulu enne makse | -17.551 | -23.222 | -22.682 | -26.543 | -27.769 |
| Netotulu pärast makse | -17.551 | -23.222 | -22.682 | -26.543 | -27.769 |
| Netotulu enne erikulusid | -17.551 | -23.222 | -22.682 | -26.543 | -27.769 |
| Netotulu | -17.551 | -23.222 | -22.682 | -26.543 | -27.769 |
| Arvestatav tulu, v a erikulud | -17.551 | -23.222 | -22.682 | -26.543 | -27.769 |
| Arvestatav tulu, koos erikuludega | -17.551 | -23.222 | -22.682 | -26.543 | -27.769 |
| Jaotamisele kuuluv netotulu | -17.551 | -23.222 | -22.682 | -26.543 | -27.769 |
| Keskmine jaotamisele kuuluv aktsia kohta | 68.9461 | 68.9855 | 69.0229 | 77.266 | 87.8029 |
| Jaotatav EPS, v a erakorralised kulud | -0.25456 | -0.33662 | -0.32862 | -0.34353 | -0.31627 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.25456 | -0.33662 | -0.32862 | -0.34353 | -0.31627 |
- Aastas
- Kvartalis
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Käibevarad kokku | 18.528 | 103.544 | 181.562 | 202.923 | 151.585 | 191.099 |
| Raha ja lühiajalised investeeringud | 16.994 | 97.21 | 178.664 | 190.945 | 146.323 | 186.535 |
| Raha ja ekvivalendid | 10.495 | 23.054 | 48.995 | 24.869 | 28.193 | 125.806 |
| Lühiajalised investeeringud | 6.499 | 74.156 | 129.669 | 166.076 | 118.13 | 60.729 |
| Prepaid Expenses | 1.369 | 1.208 | 2.594 | 11.291 | 4.985 | 4.564 |
| Other Current Assets, Total | 0.165 | 0.126 | 0.304 | |||
| Total Assets | 19.359 | 104.247 | 186.747 | 205.727 | 153.825 | 202.318 |
| Property/Plant/Equipment, Total - Net | 0.077 | 0.069 | 2.905 | 2.644 | 2.033 | 1.432 |
| Other Long Term Assets, Total | 0.754 | 0.634 | 2.28 | 0.16 | 0.207 | 1.72 |
| Total Current Liabilities | 9.311 | 16.31 | 14.415 | 17.636 | 9.857 | 18.366 |
| Accounts Payable | 0.899 | 1.311 | 1.973 | 2.503 | 0.231 | 2.728 |
| Accrued Expenses | 4.567 | 5.8 | 12.442 | 15.133 | 9.626 | 15.638 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2.7 | 3.108 | 0 | |||
| Other Current Liabilities, Total | 1.145 | 6.091 | 0 | |||
| Total Liabilities | 15.422 | 19.3 | 16.329 | 19.379 | 11.119 | 69.381 |
| Total Long Term Debt | 6.098 | 2.99 | 0 | 0 | 0 | 50.32 |
| Long Term Debt | 6.098 | 2.99 | 0 | 50.32 | ||
| Other Liabilities, Total | 0.013 | 0 | 1.914 | 1.743 | 1.262 | 0.695 |
| Total Equity | 3.937 | 84.947 | 170.418 | 186.348 | 142.706 | 132.937 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | ||
| Common Stock | 0.002 | 0.004 | 0.006 | 0.007 | 0.007 | 0.008 |
| Additional Paid-In Capital | 426.895 | 535.503 | 693.534 | 812.133 | 819.549 | 899.798 |
| Retained Earnings (Accumulated Deficit) | -422.959 | -450.516 | -523.064 | -625.872 | -676.858 | -766.856 |
| Other Equity, Total | -0.001 | -0.044 | -0.058 | 0.08 | 0.008 | -0.013 |
| Total Liabilities & Shareholders’ Equity | 19.359 | 104.247 | 186.747 | 205.727 | 153.825 | 202.318 |
| Total Common Shares Outstanding | 23.447 | 44.4088 | 59.4565 | 68.8825 | 68.9461 | 84.6779 |
| Laekumata arved, neto | 5 | 0 | 0.687 | 0.277 | ||
| Accounts Receivable - Trade, Net | 5 | 0 | 0.687 | 0.277 | ||
| Property/Plant/Equipment, Total - Gross | 0.39 | 3.035 | 3.429 | 3.487 | 3.556 | |
| Accumulated Depreciation, Total | -0.321 | -0.13 | -0.785 | -1.454 | -2.124 | |
| Long Term Investments | 8.067 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 133.273 | 113.813 | 119.576 | 191.099 | 192.046 |
| Raha ja lühiajalised investeeringud | 125.458 | 106.134 | 113.788 | 186.535 | 188.559 |
| Raha ja ekvivalendid | 43.326 | 32.897 | 68.963 | 125.806 | 73.995 |
| Lühiajalised investeeringud | 82.132 | 73.237 | 44.825 | 60.729 | 114.564 |
| Laekumata arved, neto | 0.265 | 0.227 | 0.069 | ||
| Accounts Receivable - Trade, Net | 0.265 | 0.227 | 0.069 | ||
| Prepaid Expenses | 7.55 | 7.452 | 5.719 | 4.564 | 3.487 |
| Total Assets | 136.682 | 117.041 | 122.902 | 202.318 | 200.642 |
| Property/Plant/Equipment, Total - Net | 1.963 | 1.781 | 1.605 | 1.432 | 1.263 |
| Other Long Term Assets, Total | 1.446 | 1.447 | 1.721 | 1.72 | 2.448 |
| Total Current Liabilities | 7.909 | 8.959 | 11.741 | 18.366 | 14.039 |
| Accounts Payable | 1.606 | 1.05 | 0.764 | 2.728 | 0.199 |
| Accrued Expenses | 6.303 | 7.909 | 10.977 | 15.638 | 13.84 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 9.036 | 9.947 | 35.844 | 69.381 | 93.261 |
| Total Long Term Debt | 0 | 0 | 23.259 | 50.32 | 78.685 |
| Other Liabilities, Total | 1.127 | 0.988 | 0.844 | 0.695 | 0.537 |
| Total Equity | 127.646 | 107.094 | 87.058 | 132.937 | 107.381 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.007 | 0.007 | 0.007 | 0.008 | 0.008 |
| Additional Paid-In Capital | 822.054 | 824.717 | 827.365 | 899.798 | 902.217 |
| Retained Earnings (Accumulated Deficit) | -694.409 | -717.631 | -740.313 | -766.856 | -794.625 |
| Other Equity, Total | -0.006 | 0.001 | -0.001 | -0.013 | -0.219 |
| Total Liabilities & Shareholders’ Equity | 136.682 | 117.041 | 122.902 | 202.318 | 200.642 |
| Total Common Shares Outstanding | 68.9461 | 68.9979 | 69.044 | 84.6779 | 84.6779 |
| Long Term Debt | 23.259 | 50.32 | 78.685 | ||
| Long Term Investments | 8.067 | 4.885 |
- Aastas
- Kvartalis
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netotulu/algväärtus | -26.671 | -27.557 | -72.548 | -102.808 | -50.986 | -89.998 |
| Raha majandustegevusest | -23.353 | -19.632 | -54.936 | -97.911 | -44.725 | -69.431 |
| Raha majandustegevusest | 0.029 | 0.035 | 0.105 | 0.572 | 0.632 | 0.688 |
| Mittelikviidsed varad | 2.523 | 10.494 | 8.648 | 8.231 | 7.22 | 13.528 |
| Makstud intressid | 0.866 | 0.666 | 0.231 | 0 | ||
| Muutused tööjõus | 0.766 | -2.604 | 8.859 | -3.906 | -1.591 | 6.351 |
| Tulu investeeringutelt | 27.128 | -67.528 | -54.111 | -34.347 | 47.957 | 48.589 |
| Kapitalikulutused | -0.042 | -0.027 | -0.529 | -0.315 | -0.021 | -0.087 |
| Muud rahavood investeeringutelt, kokku | 27.17 | -67.501 | -53.582 | -34.032 | 47.978 | 48.676 |
| Rahavood investeeringutelt | -0.986 | 99.719 | 134.988 | 108.132 | 0.092 | 118.455 |
| Aktsiate emiteerimine (tagasiost), neto | 0 | 102.856 | 141.641 | 108.132 | 0.092 | 70.718 |
| Laenu väljastamine (kustutamine), neto | -0.986 | -3.137 | -6.653 | 0 | 47.737 | |
| Rahaline kogumuutus | 2.789 | 12.559 | 25.941 | -24.126 | 3.324 | 97.613 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -17.551 | -40.773 | -63.455 | -89.998 | -27.769 |
| Cash From Operating Activities | -20.561 | -39.775 | -55.188 | -69.431 | -25.362 |
| Cash From Operating Activities | 0.164 | 0.339 | 0.515 | 0.688 | 0.169 |
| Non-Cash Items | 2.701 | 5.8 | 8.988 | 13.528 | 5.91 |
| Changes in Working Capital | -5.875 | -5.141 | -1.236 | 6.351 | -3.672 |
| Cash From Investing Activities | 35.694 | 44.373 | 72.666 | 48.589 | -50.99 |
| Capital Expenditures | -0.094 | -0.087 | -0.087 | -0.087 | 0 |
| Other Investing Cash Flow Items, Total | 35.788 | 44.46 | 72.753 | 48.676 | -50.99 |
| Cash From Financing Activities | 0 | 0.106 | 23.292 | 118.455 | 24.541 |
| Financing Cash Flow Items | 0 | ||||
| Net Change in Cash | 15.133 | 4.704 | 40.77 | 97.613 | -51.811 |
| Issuance (Retirement) of Stock, Net | 0.106 | 0.205 | 70.718 | -0.459 | |
| Issuance (Retirement) of Debt, Net | 23.087 | 47.737 | 25 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 12.1633 | 10300000 | 0 | 2022-09-30 | LOW |
| TCG Crossover Management, LLC | Investment Advisor | 6.9737 | 5905400 | 0 | 2022-09-30 | MED |
| Commodore Capital LP | Hedge Fund | 6.7766 | 5738500 | 0 | 2022-09-30 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.3281 | 3665062 | 108020 | 2022-09-30 | LOW |
| Foresite Capital Management, LLC | Private Equity | 4.0492 | 3428898 | 0 | 2022-09-30 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 2.9223 | 2474659 | -169647 | 2022-09-30 | LOW |
| Lynx1 Capital Advisors LLC | Investment Advisor | 2.7466 | 2325833 | -263846 | 2022-09-30 | MED |
| Baker Bros. Advisors LP | Hedge Fund | 2.5631 | 2170464 | 0 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2306 | 1888905 | -8462 | 2022-09-30 | LOW |
| Altium Capital Management LP | Investment Advisor/Hedge Fund | 2.0666 | 1750000 | 0 | 2022-09-30 | HIGH |
| Dafna Capital Management, LLC | Hedge Fund | 2.0114 | 1703235 | -84334 | 2022-09-30 | LOW |
| Laurion Capital Management LP | Hedge Fund | 1.9082 | 1615900 | 40631 | 2022-09-30 | HIGH |
| Millennium Management LLC | Hedge Fund | 1.8115 | 1533982 | -1481514 | 2022-09-30 | HIGH |
| 683 Capital Management LLC | Hedge Fund | 1.7359 | 1470000 | 0 | 2022-09-30 | MED |
| Citadel Advisors LLC | Hedge Fund | 1.5962 | 1351657 | 41780 | 2022-09-30 | HIGH |
| Hudson Bay Capital Management LP | Hedge Fund | 1.5647 | 1325000 | -174900 | 2022-09-30 | HIGH |
| Affinity Asset Advisors LLC | Hedge Fund | 1.524 | 1290511 | -81733 | 2022-09-30 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.473 | 1247365 | 169679 | 2022-09-30 | LOW |
| Medical Strategy GmbH | Investment Advisor | 1.3189 | 1116869 | 0 | 2022-09-30 | LOW |
| Great Point Partners, LLC | Hedge Fund | 0.9441 | 799439 | 799439 | 2022-09-30 |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group +485000+
Kauplejad
65000+
Igakuiste aktiivsete klientide arv
$48000000+
Igakuine investeerimise maht
$28000000+
Proovige nüüd Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Kauplemise vahendustasu
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finantsvõimendus
20:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Cymabay Therapeu Company profile
Ettevõttest Cymabay Therapeu
CymaBay Therapeutics, Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõte on keskendunud maksa- ja muude krooniliste haiguste patsientide ravimeetodite väljatöötamisele ja kättesaadavaks tegemisele. Ettevõtte tooteprogrammi kuulub kolm kliinilises staadiumis olevat tootekandidaati, nagu seladelpar, MBX-2982 ja CB-0406. Samuti on ettevõttel üks prekliinilises staadiumis olev tootekandidaat CB-001. Ettevõtte juhtiv tootekandidaat seladelpar on tugev ja selektiivne peroksisoomse proliferaatori aktiveeritud delta retseptori (PPARd) agonist, mis reguleerib otseselt või kaudselt sapphapete/steroolide sünteesiga, lipiidide ja glükoosi metabolismiga, põletiku ja fibroosiga seotud geene. Selle MBX-2982 on suunatud G-valguga seotud retseptorile 119 (GPR119), retseptorile, mis suhtleb bioaktiivsete lipiididega, mis teadaolevalt stimuleerivad glükoosist sõltuvat insuliini sekretsiooni. CB-001 on suunatud G-valguga seotud retseptorile 120 (GPR120), mis on omega-3-rasvhapete, näiteks dokosaheksaeenhappe (DHA) retseptor.
| Industry: | Bio Therapeutic Drugs |
Suite 130
7999 Gateway Blvd
NEWARK
CALIFORNIA 94560
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 485,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com